

Attorney Docket No.
15270-14Serial No.
08/186,269

LIST OF PATENTS AND PUBLICATIONS
FOR APPLICANT'S INFORMATION
DISCLOSURE STATEMENT
(Use Several Sheets if Necessary)

Applicant
MARY M. BENDIG ET AL.Filing Date
January 25, 1994Group
Unassigned

Reference Designation U.S. PATENT DOCUMENTS

Examiner Initial	Document No.	Publn. Date	Name	Class	Subcl:	File Date If Approp
------------------	--------------	-------------	------	-------	--------	---------------------

A1

FOREIGN PATENT DOCUMENTS

Document No.	Publn. Date	Country	Class	Subcl:	Trans. Yes No
B1	239,400	09/30/87	Winter	EP	C12N 15/00
B2	330,506	08/30/89	Hemler	EP	C07K 15/06
B3	90/07861	07/26/90	Queen	PCT	C12P 21/00
B4	91/05038	04/18/91	Rubin et al.	PCT	C12N 5/06

OTHER ART (Including Author, Title, Date, Pertinent Pages, Etc.)

C1	Dijkstra et al., "Multiple sclerosis: some possible therapeutic opportunities," <i>TIPS Reviews</i> 14:124-129 (April 1993) (Elsevier Science Publishers Ltd., UK)
C2	Elices et al., "VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site," <i>Cell</i> 60:577-584 (1990)
C3	Kettleborough et al., "Humanization of a mouse monoclonal antibody by CDR-grafting: the importance of framework residues on loop conformation," <i>Protein Engineering</i> 4(7):773-783 (1991)
C4	Yednock et al., "Prevention of experimental autoimmune encephalomyelitis by antibodies against $\alpha 4 \beta 1$ integrin," <i>Nature</i> 356:63-66 (1992)

EXAMINER

DATE CONSIDERED

PHILIP GAMBEL

9/21/94

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.